ROSSARINSEROSSARI BIOTECH LIMITEDMediumNeutral
Announced Fri, 24 Jul · 20:26 IST

Q1 FY27 call transcript: revenue up 28% YoY, guides for 15% steady-state EBITDA margin

Mgmt Guided Margin ImprovementInvestor Communications View source PDF

ROSSARI · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
1-day move
₹490.00
prior close
₹491.80
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.8+1.3+0.9
Up moveDown movePending
AI summary

Q1 FY27 revenue up 28% YoY to Rs. 697.2 crore, highest ever. EBITDA up 18.7% to Rs. 80.6 crore at 11.6% margin versus 12.5% YoY. PAT up 4.5% to Rs. 35.1 crore. Core B2B EBITDA margin at 14%. Exports grew 21% YoY. Management guided 11.6% as base margin, targeting 15% steady-state EBITDA in 2-3 years via B2C exit, better product mix and capacity ramp-up. Thailand plant operational with Rs. 2-3 crore revenue, Saudi greenfield project in progress. Net debt down to Rs. 248 crore from Rs. 280 crore.

Likely market impact

Margin guidance of 15% steady-state and 11.6% as base signals confidence in improvement; B2C exit could add 2-3% to margins over time.